Chatsworth-based Natrol has signed a patent licensing agreement Oekopharm GmbH of Austria for the manufacture, sales, distribution and marketing of nicotinamide adenine dinucleotide hydride (NADH) in North America. NADH is the coenzyme form of vitamin B3, which is used by the body to burn food into energy. Natrol announced it will release NADH in 10-milligram and 20-milligram tablets, and that they will be distributed in health food stores and online.
